Bill Ackman Eyes New Fund to Bet Against Market Complacency 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Britain Courts Anthropic Amid US Defense Department Dispute 
NORCROSS, Ga., Aug. 31, 2016 -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Peter G. Traber, M.D., the Company's president, chief executive officer and chief medical officer, will present at Rodman & Renshaw 18th Annual Global Investment Conference on Monday, September 12, 2016 at 3:50 p.m. Eastern time. The conference is being held at the New York Palace Hotel in New York City on September 11-13, 2016.
A live webcast of the presentation may be accessed on the conference’s website at http://wsw.com/webcast/rrshq26/galt. The webcast and presentation will be archived for 90 days following the event on the company’s website at www.galectintherapeutics.com.
About Galectin Therapeutics
Galectin Therapeutics is developing promising therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.
Contacts: Jack Callicutt, Chief Financial Officer (678) 620-3186 [email protected]
